Table II.
Stage at diagnosis
| Stage | Prepandemic patients (n = 246) | Postpandemic patients (n = 246) | P value |
|---|---|---|---|
| I | 100 (40.7%) | 70 (28.5%) | .0059 |
| IA | 45 (18.3%) | 32 (13.0%) | .1361 |
| IB | 55 (22.4%) | 38 (15.5%) | .0650 |
| II | 57 (23.2%) | 55 (22.4%) | .9144 |
| IIA | 23 (9.4%) | 21 (8.5%) | .8746 |
| IIB | 21 (8.5%) | 18 (7.3%) | .7390 |
| IIC | 13 (5.3%) | 16 (6.5%) | .7025 |
| III | 52 (21.1%) | 75 (30.5%) | .0232 |
| IIIA | 13 (5.3%) | 17 (6.9%) | .5726 |
| IIIB | 18 (7.3%) | 25 (10.2%) | .3383 |
| IIIC | 20 (8.1%) | 30 (12.2%) | .1789 |
| IIID | 1 (0.4%) | 3 (1.2%) | .6235 |
| IV | 37 (15.0%) | 46 (18.7%) | .3355 |
| IV- M1a | 6 (2.4%) | 6 (2.4%) | >.99 |
| IV - M1b | 7 (2.8%) | 5 (2.0%) | .7716 |
| IV - M1c | 21 (8.5%) | 19 (7.7%) | .8692 |
| IV - M1d | 4 (1.6%) | 16 (6.5%) | .0102 |
Bolded P-values correspond to statistically signficant differences between the pre- and post-pandemic cohorts.